Adial Pharmaceuticals Earnings Estimate
| ADIL Stock | USD 2.48 0.15 6.44% |
Adial Pharmaceuticals Earnings Estimation Breakdown
The calculation of Adial Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Adial Pharmaceuticals is estimated to be -2.776675 with the future projection ranging from a low of -3.225 to a high of -1.98. Please be aware that this consensus of annual earnings estimates for Adial Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-3.23 Lowest | Expected EPS | -1.98 Highest |
Adial Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Adial Pharmaceuticals' value are higher than the current market price of the Adial Pharmaceuticals stock. In this case, investors may conclude that Adial Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Adial Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 3 | 42.14% | -0.08 | -2.776675 | -15.0 |
Adial Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Adial Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Adial Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Adial Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Adial Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Adial Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Adial Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Adial Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Adial Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-11-13 | 2025-09-30 | -0.39 | -0.08 | 0.31 | 79 | ||
2025-08-13 | 2025-06-30 | -0.39 | -0.18 | 0.21 | 53 | ||
2025-05-12 | 2025-03-31 | -0.495 | -0.34 | 0.155 | 31 | ||
2025-03-31 | 2024-12-31 | -0.33 | -0.15 | 0.18 | 54 | ||
2024-11-12 | 2024-09-30 | -0.44 | -0.38 | 0.06 | 13 | ||
2024-08-13 | 2024-06-30 | -0.53 | -0.59 | -0.06 | 11 | ||
2024-05-14 | 2024-03-31 | -0.33 | -0.62 | -0.29 | 87 | ||
2024-02-20 | 2023-12-31 | -0.76 | -1.35 | -0.59 | 77 | ||
2023-11-14 | 2023-09-30 | -1.13 | -1.18 | -0.05 | 4 | ||
2023-08-21 | 2023-06-30 | -1.5 | 0.96 | 2.46 | 164 | ||
2023-05-12 | 2023-03-31 | -0.14 | -0.11 | 0.03 | 21 | ||
2023-03-30 | 2022-12-31 | -0.15 | -0.105 | 0.045 | 30 | ||
2022-11-14 | 2022-09-30 | -0.18 | -0.12 | 0.06 | 33 | ||
2022-08-15 | 2022-06-30 | -0.14 | -0.16 | -0.02 | 14 | ||
2022-05-16 | 2022-03-31 | -0.17 | -0.13 | 0.04 | 23 | ||
2022-03-28 | 2021-12-31 | -0.21 | -0.28 | -0.07 | 33 | ||
2021-11-15 | 2021-09-30 | -0.22 | -0.22 | 0.0 | 0 | ||
2021-08-12 | 2021-06-30 | -0.2 | -0.25 | -0.05 | 25 | ||
2021-05-17 | 2021-03-31 | -0.15 | -0.3 | -0.15 | 100 | ||
2021-03-22 | 2020-12-31 | -0.25 | -0.24 | 0.01 | 4 | ||
2020-11-13 | 2020-09-30 | -0.18 | -0.24 | -0.06 | 33 | ||
2020-08-13 | 2020-06-30 | -0.18 | -0.16 | 0.02 | 11 | ||
2020-03-20 | 2019-12-31 | -0.19 | -0.19 | 0.0 | 0 | ||
2019-11-14 | 2019-09-30 | -0.17 | -0.17 | 0.0 | 0 | ||
2019-08-13 | 2019-06-30 | -0.18 | -0.21 | -0.03 | 16 | ||
2019-05-13 | 2019-03-31 | -0.17 | -0.27 | -0.1 | 58 | ||
2019-02-19 | 2018-12-31 | -0.18 | -0.27 | -0.09 | 50 | ||
2018-11-14 | 2018-09-30 | -0.26 | -0.85 | -0.59 | 226 | ||
2017-11-22 | 2017-09-30 | 0 | -0.04 | -0.04 | 0 | ||
2017-09-07 | 2017-06-30 | 0 | -0.04 | -0.04 | 0 | ||
2017-06-21 | 2017-03-31 | 0 | -0.03 | -0.03 | 0 |
About Adial Pharmaceuticals Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Adial Pharmaceuticals earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Adial Pharmaceuticals estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Adial Pharmaceuticals fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -73.8 M | -70.1 M | |
| Retained Earnings Total Equity | -28.4 M | -29.8 M | |
| Earnings Yield | (0.81) | (0.85) | |
| Price Earnings Ratio | (1.28) | (1.34) | |
| Price Earnings To Growth Ratio | 0.02 | 0.02 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Adial Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Adial Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Adial's balance sheet. Smart investors calculate Adial Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Adial Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Adial Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Adial Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.